KRAS and neoplasm: Although the combination of MEK inhibitors with standard therapy (gemcitabine/Nab-paclitaxel) reduced tumor growth and metastasis in PDXs (patient-derived xenograft models), it may also elicit KRAS mutation, which can contribute to tumor heterogeneity.